Do we Still Need Human Embryonic Stem Cells for Stem Cell-Based Therapies? Epistemic and Ethical Aspects

Stem Cell Reviews and Reports

Volumn 7, Issue 4, 2011, Pages 761-774

  Hug, Kristina ^a,b   Hermerén, Göran ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Ethical controversy; Human embryonic stem cells; Human induced pluripotent stem cells; Patient safety; Treatment accessibility; Treatment efficacy

Indexed keywords

ARTICLE; CYTOLOGY; EMBRYONIC STEM CELL; ETHICS; HUMAN; PLURIPOTENT STEM CELL; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH; TRANSPLANTATION;

EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 82355161200     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-011-9257-3     Document Type: Article

References (61)

1. Jung, K. W. (2009). Perspectives on human stem cell research. Journal of Cellular Physiology, 220, 535-537.
2. Amabile, G., & Meissner, A. (2009). Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends in Molecular Medicine, 15, 59-68.
3. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663-676.
4. Williams, D. A. (2009). Rapid development of pluripotent stem cells as a potential therapeutic modality. Molecular Therapy, 17, 929-930.
5. Fleischhauer, K., & Hermerén, G. (2006). Goals of medicine in the course of history and today. A study in the history and philosophy of medicine. Stockholm: Kungl. Vitterhets Historie och Antikvitets Akademien.
6. Hermerén, G. (2008). European values-and others. Europe's shared values: towards and ever-closer union? European Review, 16, 373-385.
7. Kiskinis, E., & Eggan, K. (2010). Progress toward the clinical application of patient-specific pluripotent stem cells. The Journal of Clinical Investigation, 120, 51-59.
8. Hovatta, O. (2011). The obstacles on the road to clinical applications of stem cell-based therapies: what has been done and what remains to be done? In K. Hug & G. Hermerén (Eds.), Translational stem cell research: Issues beyond the debate on the moral status of the human embryo (pp. 103-111). New York: Springer.
9. Salewski, R. P. F., Eftekharpour, E., & Fehlings, M. G. (2010). Are induced pluripotent stem cells the future of cell-based regenerative therapies for spinal cord injury? Journal of Cellular Physiology, 222, 515-521.
10. Hwang, D.-Y., Kim, D.-S., & Kim, D.-W. (2010). Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems. Journal of Cellular Biochemistry, 109, 292-301.
11. Ou, L., Wang, X., & Zou, F. (2010). Is iPS cell the Panacea? IUBMB Life, 62, 170-175.
12. Ronaghi, M., Erceg, S., Moreno-Manzano, V., & Stojkovic, M. (2010). Challenges of stem cell therapy for spinal cord injury: human embryonic stem cells, endogenous neural stem cells, or induced pluripotent stem cells? Stem Cells, 28, 93-99.
13. Cox, J. L., & Rizzino, A. (2010). Induced pluripotent stem cells: what lies beyond the paradigm shift. Experimental Biology and Medicine: Journal of the Society for Experimental Biology and Medicine, 235, 148-158.
14. Broxmeyer, H. E. (2010). Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell, 6, 21-24.
15. Holden, C., & Vogel, G. (2008). A seismic shift for stem cell research. Science, 319, 560-563.
16. Lengner, C. J. (2010). iPS cell technology in regenerative medicine. Annals of the New York Academy of Sciences, 1192, 38-44.
17. Takahashi, K. (2010). Direct reprogramming 101. Development, Growth & Differentiation, 52, 319-333.
18. Dressel, R., Guan, K., Nolte, J., et al. (2009). Multipotent adult germ-line stem cells, like other pluripotent stem cells, can be killed by Cytotoxic T Lymphocytes despite low expression of major histocompatibility complex class I molecules. Biology Direct, 4, 31-50.
19. Pozzobon, M., Ghionzoli, M., & De Coppi, P. ES, iPS, MSC, and AFS cells. (2010). Stem Cells Exploitation for Pediatric Surgery: Current Research and Perspective. Pediatric Surgery International, 26, 3-10.
20. Ayetey, H. (2011). Therapeutic possibilities of induced pluripotent stem cells. In K. Hug & G. Hermerén (Eds.), Translational stem cell research: Issues beyond the debate on the moral status of the human embryo (pp. 77-90). New York: Springer.
21. Hyun, I. (2009). Clarifying the president's council's clarification of the Obama stem cell policy. In Bioethics Forum. Diverse Commentary on Issues in Bioethics [cited 2010 April 9]; Available from: URL: http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=3308.
22. Meyer, A. K., Maisel, M., & Hermann, A. (2010). Restorative approaches in Parkinson's disease: which cell type wins the race? Journal of the Neurological Sciences, 289, 93-104.
23. Betts, D. H., & Kalionis, B. (2010). Viable iPSC mice: a step closer to therapeutic applications in humans? Molecular Human Reproduction, 16, 57-62.
24. Magill, G., & Neaves, W. B. (2009). Ontological and ethical implications of direct nuclear reprogramming. Kennedy Institute of Ethics Journal, 19, 23-32.
25. Boland, M. J., Hazen, J. L., Nazor, K. L., et al. (2009). Adult mice generated from induced pluripotent stem cells. Nature, 461, 91-94.
26. Condic, M. L., Lee, P., & George, R. P. (2009). Ontological and ethical implications of direct nuclear reprogramming: response to Magill and Neaves. Kennedy Institute of Ethics Journal, 19, 33-40.
27. Peters, T. (2009). "Of Mice and Men": making babies from stem cells. Theology and Science, 7, 311-314.
28. Kaebnick, G. E. (2008). Response to Cynthia B. Cohen and Bruce P. Brandhorst. Getting Clear on the Ethics of iPS Cells. 02/01/2008. In Bioethics Forum. Diverse Commentary on Issues in Bioethics [cited 2010 April 9]; Available from: URL: http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=706.
29. Cohen, C. B., & Brandhorst, B. P. (2008). Getting clear on the ethics of iPS cells. In Bioethics Forum. Diverse Commentary on Issues in Bioethics [cited 2010 April 9]; Available from: URL: http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=710&terms=iPS+and+%23filename+*.html.
30. Lo, B., Parham, L., Alvarez-Buylla, A., et al. (2010). Cloning mice and men: prohibiting the use of iPS cells for human reproductive cloning. Cell Stem Cell, 6, 16-20.
31. Kang, L., Wang, J., Zhang, Y., Kou, Z., & Gao, S. (2009). iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell, 5, 135-138.
32. Zhao, X.-Y., Li, W., Lv, Z., et al. (2009). iPS cells produce viable mice through tetraploid complementation. Nature, 461, 86-90.
33. De Souza, N. (2010). Primer: induced pluripotency. Nature Methods, 7, 20-22.
34. Liu, S. V. (2009). Embryonic and adult education on stem cells. Correspondence. Logical Biology, 9, 8-9.
35. Testa, G. (2009). What to do with the Grail now that we have it? iPSCs, potentiality, and public policy. Cell Stem Cell, 5, 358-359. Erratum in: Cell Stem Cell (2009), 5, 567.
36. Neri, D. (2009). The race toward Ethically universally acceptable human pluripotent (Embryonic-Like) stem cells: only a problem of sources? Bioethics [Epub ahead of print]. Article first published online: 30 NOV 2009.
37. Urbach, A., Bar-Nur, O., Daley, G. Q., & Benvenisty, N. (2010). Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell, 6, 407-411.
38. Kim, K.-S. (2010). Induced pluripotent stem (iPS) cells and their future in psychiatry. Neuropsychopharmacology, 35, 346-349.
39. Sendtner, M. (2009). Stem cells: tailor-made diseased neurons. Nature, 457, 269-271.
40. The European Parliament and the Council of the European Union. (2001). Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use [cited 2010 March 12]; Available from: URL: http://www.wctn.org.uk/downloads/EU_Directive/Directive.pdf.
41. The European Parliament and the Council. (2004). Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on Setting Standards of Quality and Safety for the Donation, Procurement, Testing, Processing, Preservation, Storage and Distribution of Human Tissues and Cells [cited 2010 March 12]; Available from: URL: http://www.who.int/ethics/en/ETH_EU_Directive_2004_23_EC.pdf.
42. The European Parliament. (2007). Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No 726/2004 [cited 2010 March 14]; Available from: URL: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf.
43. Council of Europe. (1950). Convention for the Protection of Human Rights and Fundamental Freedoms as amended by Protocol No. 11 [cited 2010 March 17]; Available from: http://www.echr.coe.int/NR/rdonlyres/D5CC24A7-DC13-4318-B457-5C9014916D7A/0/EnglishAnglais.pdf.
44. Council of Europe. (1997). Convention for the Protection of Human Rights and Dignity of the Human Being with Regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine. Oviedo, 4. IV [cited 2010 March 14]; Available from: URL: http://conventions.coe.int/Treaty/Commun/QueVoulezVous.asp?NT=164&CL=ENG.
45. The World Medical Association. (2008). Declaration of Helsinki 2008 [cited 2010 March 14]; Available from: URL: http://www.wma.net/e/ethicsunit/helsinki.htm.
46. Council for International Organizations of Medical Sciences (CIOMS). (2002). International Ethical Guidelines for Biomedical Research Involving Human Subjects [cited 2010 March 12]; Available from: URL: http://www.cioms.ch/frame_guidelines_nov_2002.htm.
47. International Society for Stem Cell Research. (2008). ISSCR Guidelines for the Clinical Translation of Stem Cells. December 3 [cited 2010 March 12]; Available from: URL: http://www.isscr.org/clinical_trans/pdfs/ISSCRGLClinicalTrans.pdf.
48. Presidents of the European Parliament, the Council and the Commission at the European Council. (2000). Charter of Fundamental Rights of the European Union (2000/C 364/01). 7 December 2000 [cited 2010 March 12]; Available from: URL: http://www.europarl.europa.eu/charter/pdf/text_en.pdf.
49. European Medicines Agency. (2002). CPMP/ICH/135/95. ICH Topic E 6 (R1). Guideline for Good Clinical Practice. Note for Guidance on Good Clinical Practice, July [cited 2010 March 15]; Available from: URL: http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf.
50. Yim, R. (2005). Administrative and research policies required to bring cellular therapies from the research laboratory to the patient's bedside. Transfusion, 45, 144S-158S.
51. Lo, B., Kriegstein, A., & Grady, D. (2008). Clinical trials in stem cell transplantation: guidelines for scientific and ethical review. Clinical Trials, 5, 517-522.
52. Sugarman, J. (2007). Ethics and stem cell therapeutics for cardiovascular disease. Progress in Cardiovascular Diseases, 50, 1-6.
53. Tzamaloukas, A. H., Konstantinov, K. N., Agaba, E. I., Raj, D. S., Murata, G. H., & Glew, R. H. (2008). Twenty-first century ethics of medical research involving human subjects: achievements and challenges. International Urology and Nephrology, 40, 153-163.
54. Maienschein, J., Sunderland, M., Ankeny, R. A., & Robert, J. S. (2008). The ethos and ethics of translational research. The American Journal of Bioethics, 8, 43-51.
55. Marks, J. H. (2008). Expedited industry-sponsored translational research: a seductive but hazardous cocktail? The American Journal of Bioethics, 8, 56-58.
56. Bentham, J. (1960). Of the four sanctions or sources of pain and pleasure. In W. Harrison (Ed.), A fragment on government and an introduction to the principles of morals and legislation (pp. 147-150). Oxford: Basil Blackwell.
57. Singer, P. (1993). Practical ethics. Cambridge: Cambridge University Press.
58. Brownsword, R. (2009). Human dignity, ethical pluralism, and the regulation of modern biotechnologies. In T. Murphy (Ed.), New technologies and human rights (pp. 19-84). Oxford: Oxford University Press.
59. Fagot-Largeault, A. (1994). Abortion and arguments from potential. In R. Gillon (Ed.), Principles of health care ethics (pp. 577-586). Chichester: John Wiley & Sons.
60. Sahlin, N.-E., Persson, J., & Vareman, N. (2011). Unruhe und Ungewissheit-Stem cells and risks. In K. Hug & G. Hermerén (Eds.), Translational stem cell research: Issues beyond the debate on the moral status of the human embryo (pp. 421-430). New York: Springer.
61. London, A. J., Kimmelman, J., & Emborg, M. E. (2010). Beyond access vs. protection in trials of innovative therapies. Science, 328, 829-830.